They may have to turn to scumbags’
MARCUS Davies believes last week s court decision will only act to push MS sufferers into the murky world of drug dealers. Instead of giving a donation of £5 for pain-relieving chocolate bars, Mr Davies told The Hunts Post that MS sufferers would have to
MARCUS Davies believes last week's court decision will only act to push MS sufferers into the murky world of drug dealers.
Instead of giving a donation of £5 for pain-relieving chocolate bars, Mr Davies told The Hunts Post that MS sufferers would have to "pay £25 to drug-dealing scumbags"
He said: "I'm ever so proud to have helped so many people, but these people are now in great jeopardy."
Mr Davies said the business, THC4MS (Therapeutic Help from Cannabis for Multiple Sclerosis) never paid for the cannabis it supplied. It was given to them by UK growers.
"We never actually bought cannabis from the illegal market. (Our suppliers) are good, honest people who know that this is the best medicine in the world."
He added: "In our mission statement, it says the supply of cannabis chocolate bars will continue until there was a viable alternative.
Most Read
- 1 Horse rider injured in crash on Ramsey Road in Warboys
- 2 Fire Crews called to a blaze that started in a flat in St Ives
- 3 Staff threatened with sledgehammer in armed robbery at St Neots jewellers
- 4 One arrest and cars seized on busy day for cops
- 5 House fire that killed two children will not have further electrical checks
- 6 Mother pays tribute to “much-loved” son who died near Fen Drayton
- 7 St Ives man undergoes pioneering heart treatment
- 8 Drug dealers operating the ‘Marlo’ and ‘Star’ lines have been jailed
- 9 Hundreds gather to see Santa on The Quay in St Ives
- 10 Hinchingbrooke Hospital get share of £4.5m to 'improve care'
"That has happened, there is now Sative, a natural product with plant extracts that costs £100 a bottle."
Mr Davies said the bottle contains 52 doses but only lasts two weeks once opened. This means a cost of £200 a month - a price the NHS cannot afford.
He said treatment had been trialled in Europe where the manufacturers, GW Pharmaceuticals, were hoping to get a licence.
Mr Davies, who said he is a shareholder in the company, added: "It was cleared for use in the UK in November 2005 but primary care trusts decided that the drug was too expensive.
